Lars Bruening, CEO, Bayer UK & Ireland
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Address: Magdalen Centre The Oxford Science Park Oxford OX4 4GA,United Kingdom
Tel: +44 (0)1865 784574
Web: http://www.circassia.co.uk/
Circassia is a specialty biopharmaceutical company focused on developing world-class immunotherapies. These include a new class of T-cell vaccines designed to treat a broad range of allergies, and therapies to combat autoimmune conditions such as rheumatoid arthritis and psoriasis. The Company has made rapid progress since its establishment in 2006, and several of its products are currently in mid- to late-stage development, having successfully completed a number of phase II clinical studies.
Circassia has a broad portfolio of immuno-based therapies, with many currently progressing through clinical development. The company has completed a number of successful phase II studies and plans to advance several products into the final stage of development in the near future.
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s…
Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical…
Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid…
Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and…
The new AI tech from Google’s DeepMind can diagnose over 50 retinal diseases with more accuracy than your optometrist. Research conducted by Nature Medicine found that a ground-breaking artificial intelligence system developed…
Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in the US. Its CEO, James…
Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse…
With a strong historic footprint in Edinburgh, Canon Medical Systems has based one of its global R&D centres in Scotland from where it develops software for its devices. Ken Sutherland,…
After 30 years in the cell therapy space, Dr Michael Leek founded TC BioPharm in Scotland. Within four years the company has forged major partnership deals and advanced its CAR…
Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of the UK’s healthcare system, its expertise in life sciences and…
See our Cookie Privacy Policy Here